Comparison of HPV DNA Detection Technologies; Hybrid Capture II (QIAGEN), Cervista™ HPV HR (Hologic UK Ltd) in a Northern Irish Screening Population
H Keegan, L Pilkington, J Jamison, R Wilson, J Carson. University of Dublin, Trinity College, Dublin, Ireland; Coombe Women and Infants University Hospital, Dublin, Ireland; Antrim Area Hospital, Antrim, United Kingdom
Background: Cervical screening programmes worldwide are moving towards HPV DNA testing as part of the population screening process. We evaluated 2 HPV detection methods on ThinPrep specimens from a cervical screening population.
Design: Cervical smear specimens from 331 women were recruited through the Antrim Area Hospital, Antrim and the residual PreservCyt was used for HPV testing. Cytological diagnoses were made in accordance with UK National Health Service Cervical Screening Programme (NHSCSP). HPV DNA was detected by Hybrid Capture (hc2) for 13 high-risk HPV types and Cervista HPV HR (Cervista) for 14 high-risk types including HPV66 which is not included in the hc2 assay. The Cervista assay includes three different HPV specific mastermixes one of which (Mix 1) contains probes for HPV66, HPV56 and HPV51. HPV66 and 51 are the joint third most common HPV types in an all Ireland study of HPV prevalence.
Results: The prevalence of HPV was 23% by hc2 and 22% by Cervista. The concordance rate was 87%. A discordant result is a positive result by one assay and negative by the other test. Using detection of HPV in specimens with mild or greater abnormalities as the true positive, there was no significant difference in the sensitivity (P=0.148) or specificity (P=0.918) of the tests.
Conclusions: There was a high rate of concordance between the hc2 assay and Cervista despite the absence of HPV66 from the hc2 assay mix. This may be due to cross-reactivity of HPV66 with other HPV probes contained in the hc2 assay. There was no statistical difference in the sensitivity or specificity of either assay. Further studies containing greater numbers of cases with severe abnormalities will be performed. This study was sponsored by Hologic Inc. and forms part of the Irish Cervical Screening Research Consortium CERVIVA funded by the Health Research Board, Ireland.
Tuesday, March 23, 2010 9:30 AM
Poster Session III # 67, Tuesday Morning